LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Home・Stock List・Innoviva Inc

Innoviva Inc

Closed

SectorHealthcare

22.13 -2.17

Buy Sell

Overview

Share price change

24h

Current

Min

22.05

Max

22.85

Key metrics
By Trading Economics
Income	-55M 187M
Sales	-20M 98M
P/E Sector Avg	3.588 50.102
EPS	0.47
Profit margin	190.415
Employees	159
EBITDA	-160M 48M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+52.12% upside

Dividends
By Dow Jones
Next Earnings	4 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-45M 1.7B
Previous open	24.3
Previous close	22.13

News Sentiment

By Acuity

63%

37%

284 / 344 Healthcare

Innoviva Inc Chart

Past performance is not a reliable indicator of future results.

Related News

27 May 2026, 21:33 UTC

Earnings

Correction to Salesforce 1Q Sales, Profit Rise Article

27 May 2026, 21:00 UTC

Acquisitions, Mergers, Takeovers

HCA Healthcare Agrees to Buy The College of Health Care Professions

27 May 2026, 20:18 UTC

Earnings

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27 May 2026, 23:49 UTC

Market Talk

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27 May 2026, 23:39 UTC

Market Talk

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27 May 2026, 23:34 UTC

Market Talk

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27 May 2026, 23:34 UTC

Market Talk

Global Equities Roundup: Market Talk

27 May 2026, 23:08 UTC

Market Talk

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27 May 2026, 22:21 UTC

Market Talk

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27 May 2026, 21:29 UTC

Hot Stocks

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27 May 2026, 21:08 UTC

Earnings

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27 May 2026, 21:02 UTC

Earnings

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27 May 2026, 20:59 UTC

Acquisitions, Mergers, Takeovers

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27 May 2026, 20:55 UTC

Earnings

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27 May 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27 May 2026, 20:48 UTC

Earnings

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27 May 2026, 20:45 UTC

Earnings

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27 May 2026, 20:34 UTC

Acquisitions, Mergers, Takeovers

Webster Financial Stockholders Approve Sale to Banco Santander

27 May 2026, 20:32 UTC

Earnings

Acquisitions, Mergers, Takeovers

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27 May 2026, 20:32 UTC

Acquisitions, Mergers, Takeovers

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27 May 2026, 20:32 UTC

Acquisitions, Mergers, Takeovers

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27 May 2026, 20:30 UTC

Earnings

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27 May 2026, 20:30 UTC

Acquisitions, Mergers, Takeovers

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27 May 2026, 20:22 UTC

Earnings

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 May 2026, 20:16 UTC

Earnings

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 May 2026, 20:13 UTC

Earnings

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27 May 2026, 20:13 UTC

Earnings

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27 May 2026, 20:13 UTC

Earnings

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27 May 2026, 20:12 UTC

Earnings

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27 May 2026, 20:12 UTC

Earnings

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Peer Comparison

Price change

Innoviva Inc Forecast

Price Target

By TipRanks

52.12% upside

12 Months Forecast

Average 34.5 USD 52.12%

High 46 USD

Low 18 USD

Based on 4 Wall Street analysts offering 12 month price targets forInnoviva Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Innoviva Inc - Dist in the past 3 months.

Sentiment

By Acuity

284 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.